Skip to main content

Table 2 Total self-efficacy score by socio-demographic and clinical variables

From: The relationship between self-efficacy and treatment satisfaction among patients with anticoagulant therapy: a cross-sectional study from a developing country

Variable Frequency % N(300) Median (Q1–Q3) Mean ± SD Mean rank P-value
Age category (years) < 0.001 b
  < 30 31 (10.3) 47.00(41.00–50.00) 44.32 ± 9.09 205.84
 30–60 163 (54.3) 41.00(35.00–46.00) 39.36 ± 9.38 158.72
  > 60 106 (35.3) 35.00(30.00–42.00) 35.23 ± 9.80 121.68
Gender 0.311 a
 Male 115 (38.3) 40.00(33.00–47.00) 39.09 ± 10.46 156.93
 Female 185 (61.7) 39.00(32.00–45.00) 37.99 ± 9.52 146.50
BMIa 0.146b
 Normal 65 (21.7) 41.00(39.00–49.00) 40.13 ± 9.51 163.11
 Overweight 136 (45.3) 39.00(34.00–45.00) 38.35 ± 9.05 147.75
 Obese 93 (31.0) 38.00(31.00–44.00) 37.09 ± 9.97 136.19
Education < 0.001 b
 Illiterate 20 (6.7) 29.50(21.75–41.50) 30.70 ± 11.37 90.18
 Elementary 43 (14.3) 35.00(28.00–41.00) 36.14 ± 9.42 123.37
 Primary 52 (17.3) 37.00(31.00–42.00) 36.45 ± 9.77 130.83  
 Secondary 54 (18.0) 41.00(36.75–48.00) 40.65 ± 9.91 167.40
 University 124 (41.3) 41.50(34.00–47.00) 39.85 ± 9.18 159.59
Income (month) 0.432b
 Less than 2000 NIS 23 (7.7) 41.00(31.00–45.00) 37.61 ± 11.70 145.93
 2000–5000 NIS 160(53.3) 39.00(31.00–45.00) 38.00 ± 9.66 140.54
 More than 5000 NIS 108(36.0) 41.00 (35.00–46.00) 39.31 ± 10.07 154.10
locality 0.675 b
 Camp 36 (12.0) 38.50(31.25–45.75) 37.53 ± 9.46 138.42
 Rural 85(28.3) 39.00(31.00–44.00) 38.11 ± 9.51 143.67
 Urban 172(57.3) 39.00(34.00–46.75) 38.76 ± 10.18 150.44
Marital status 0.103a
 Married 229(76.3) 12.00(11.00–14.00) 39.00 ± 9.52 152.59
 Unmarried (single, divorced, widowed) 67(22.3) 11.00(10.00–13.00) 36.25 ± 10.97 133.50
Employment status 0.049 a
 Employed 194(64.7) 42.00(34.00–48.00) 40.04 ± 10.26 161.07
 Unemployed 100(33.3) 38.00(32.00–44.25) 37.82 ± 9.24 140.51
Chronic co-morbid disease 0.034 b
 No co-morbid disease 42 (14.0) 42.00(35.00–47.00) 40.29 ± 8.89 166.74
 One disease 44(14.7) 42.00(34.00–49.00) 40.30 ± 10.56 164.71
 Two diseases 63(21.0) 40.00 (33.00–47.00) 39.43 ± 8.89 156.02
 Three diseases or more 146(48.7) 37.00(30.75–44.00) 36.76 ± 10.32 133.22
Indications for anticoagulant 0.001 b
 Atrial fibrillation 63 (21.0) 36.00 (27.00–41.00) 34.02 ± 10.51 115.01
 Deep vein thrombosis or Pulmonary embolism 29 (9.7) 43.00 (34.51–49.50) 42.76 ± 7.79 187.07
 Prophylaxisc 72 (24.0) 39.50 (35.00–46.75) 38.63 ± 8.83 152.99
 Other indications 136 (45.3) 41.00 (33.00–47.00) 39.40 ± 9.90 157.82
Chronic medications 0.029 a
  ≤ 4 176(58.7) 41.00(33.25–47.00) 39.32 ± 9.95 159.76
  > 4 124(41.3) 37.00(32.00–44.00) 37.11 ± 9.68 137.49
Anticoagulant drug 0.002 b
 UHF 87(29) 40.00(35.00–46.00) 39.02 ± 8.45 154.05
 Vit-K dependent 134(44.7) 35.00(30.25–42.00) 35.18 ± 9.74 119.38
 NOACs 75(25) 41.00(33.75–47.00) 39.00 ± 8.20 161.20
  1. a The statistical significance of the differences was calculated using the Mann-Whitney U test
  2. b The statistical significance of the differences was calculated using the Kruskal-Wallis test
  3. Bold P-value indicates a significant difference
  4. cPatients that received prophylactic doses of unfractionated heparin during hospital admission
  5. NIS: New Israeli Shekel (0.29 US Dollar)